Mark Brister Net Worth

The estimated Net Worth of Mark Brister is at least $108 Thousand dollars as of 6 August 2019. Mark Brister owns over 5,000 units of Obalon Therapeutics Inc stock worth over $107,656 and over the last 19 years Mark sold OBLN stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mark Brister OBLN stock SEC Form 4 insiders trading

Mark has made over 1 trades of the Obalon Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Mark bought 5,000 units of OBLN stock worth $20,000 on 6 August 2019.

The largest trade Mark's ever made was buying 5,000 units of Obalon Therapeutics Inc stock on 6 August 2019 worth over $20,000. On average, Mark trades about 333 units every 0 days since 2005. As of 6 August 2019 Mark still owns at least 38,865 units of Obalon Therapeutics Inc stock.

You can see the complete history of Mark Brister stock trades at the bottom of the page.

What's Mark Brister's mailing address?

Mark's mailing address filed with the SEC is C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD, CA, 92008.

Insiders trading at Obalon Therapeutics Inc

Over the last 8 years, insiders at Obalon Therapeutics Inc have traded over $0 worth of Obalon Therapeutics Inc stock and bought 3,260,355 units worth $6,939,913 . The most active insiders traders include Parters Vii L Pblair James ..., Partners X Lp Inter West Ma..., and David Moatazedi. On average, Obalon Therapeutics Inc executives and independent directors trade stock every 54 days with the average trade being worth of $432,771. The most recent stock trade was executed by William J. Plovanic on 12 November 2019, trading 65,000 units of OBLN stock currently worth $107,900.

What does Obalon Therapeutics Inc do?

Obalon Therapeutics, Inc. is a San Diego-based company focused on developing and commercializing novel technologies for weight loss.

Complete history of Mark Brister stock trades at Dexcom Inc and Obalon Therapeutics Inc

Obalon Therapeutics Inc executives and stock owners

Obalon Therapeutics Inc executives and other stock owners filed with the SEC include:

• Dr. Kelly Huang Ph.D.,
  Consultant
• Andrew Rasdal,
  Chairman of the Board, President, Chief Executive Officer
• Andrew P. Rasdal,
  CEO, Pres & Director
• Sharon Stevenson,
  Independent Director
• Lesley Howe,
  Independent Director
• Douglas Fisher,
  Independent Director
• Raymond Dittamore,
  Independent Director
• William Plovanic,
  Director
• Robert MacDonald,
  Chief Retail Officer
• Donald Young,
  Vice President of Quality Assurance
• Todd Wood,
  Vice President - Global Sales
• Lisa Metzner,
  Vice President of Marketing
• Matthew Norwood,
  Vice President of Sales
• Steve Johnson,
  Vice President - Operations
• Nooshin Hussainy,
  Chief Financial Officer
• Nooshin Hussainy,
  CFO & Sec.
• Kim P. Kamdar,
  
• Erin Morisey,
  VP Strategic Partnerships
• Partners X Lp Inter West Ma...,
  
• David Moatazedi,
  
• Vii Associates Lpblair Jame...,
  
• Parters Vii L Pblair James ...,
  
• Amy Vanden Berg,
  Chief Clinical & Reg Officer
• Kelly Huang,
  Pres & Chief Executive Officer
• Robert H Jr Mondore,
  VP of Operations
• Jonah Shacknai,
  
• Partners X Lp Inter West Ma...,
  
• Daina Schmidt,
  Vice President of Marketing
• Mark Brister,
  Chief Technology Officer